OVID News and Press, Ovid Therapeutics Inc. From 03/30/20

Soticlestat continues to appear to be safe and well-tolerated; the majority of the 11 patients showed a reduction in seizures All patients that have completed the Phase 2 ARCADE study to date have opted to enroll in the ENDYMION open-label extension study NEW YORK, March 30, 2020 (...

Ovid Therapeutics (NASDAQ: OVID ): Q4 GAAP EPS of -$0.35 beats by $0.09 . More news on: Ovid Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

Multiple clinical data readouts across Ovid’s pipeline expected in 2020 Completed financings in the fourth quarter strengthening the balance sheet NEW YORK, March 11, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to de...

NEW YORK, Feb. 25, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that Jeremy Levin, DPhil, MB, BChir, Chairman and Chief Execut...

OV101 (gaboxadol) in Neurodevelopmental Disorders: Topline Results From Pivotal Phase 3 NEPTUNE Trial in Angelman Syndrome Expected in Mid-2020 Results From Phase 2 Signal-Finding ROCKET Trial and SKY ROCKET Non-Interventional Data in Fragile X Expected by Early Q2 2020 O...

Will These Penny Stocks Make New Highs Before 2020? Penny stocks are volatile; we know this. But it’s also important to know that this volatility can lead to extremes. What I mean by this are extreme highs and extreme lows. Yesterday we wrote about a few penny stocks hitting 52-week ...

RBC Capital analyst Brian Abrahams sees a favorable risk-reward for Ovid Therapeutics (NASDAQ: OVID ) heading into next year. More news on: Ovid Therapeutics Inc., Healthcare stocks news, Stocks on the move, Read more ...

NEW YORK, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that Amit Rakhit, M.D., President and Chief Medical Officer, w...

Seasoned CNS and Rare Disease Commercial Executive Further Strengthens Executive Management Team NEW YORK, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare...

Ovid Therapeutics (NASDAQ: OVID ): Q3 GAAP EPS of -$0.43 misses by $0.06 . More news on: Ovid Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...